Brian Betts
Overview
Explore the profile of Brian Betts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Herr M, Balderman S, Wallace P, Zhang Y, Tario Jr J, Buxbaum N, et al.
Transplant Cell Ther
. 2024 May;
30(8):808.e1-808.e13.
PMID: 38801976
Haploidentical (Haplo) allogeneic HCTs (alloHCT) have been used more frequently over the last decade as survival is similar to HLA-matched related donor (MRD) alloHCTs. We aimed to identify donor and...
2.
Beckman J, DaSilva A, Aronovich E, Nguyen A, Nguyen J, Hargis G, et al.
J Thromb Haemost
. 2023 Feb;
21(5):1366-1380.
PMID: 36738826
Background: Vascular activation is characterized by increased proinflammatory, pro thrombotic, and proadhesive signaling. Several chronic and acute conditions, including Bcr-abl-negative myeloproliferative neoplasms (MPNs), graft-vs-host disease, and COVID-19 have been noted...
3.
Sumransub N, Cao Q, Juckett M, Betts B, Holtan S, Jurdi N, et al.
Transplant Cell Ther
. 2023 Jan;
29(4):263.e1-263.e7.
PMID: 36682471
Autologous hematopoietic stem cell transplantation (ASCT) improves survival for patients with chemotherapy-sensitive lymphoma. Validated scoring systems are used in the clinical setting to predict treatment toxicity and survival; however, complications...
4.
Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, et al.
Blood Adv
. 2021 Jul;
5(13):2740-2750.
PMID: 34242388
Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting...
5.
Jurdi N, Fair C, Rogosheske J, Shanley R, Arora M, Bachanova V, et al.
Transplant Cell Ther
. 2021 Apr;
27(2):179.e1-179.e4.
PMID: 33830033
Regimen-related toxicities with high-dose therapy followed by hematopoietic cell rescue leads to considerable patient distress, morbidity, and high readmission rates. Palifermin is a recombinant keratinocyte growth factor that is Food...
6.
Obeid K, Grzywacz B, Ferrieri P, Arbefeville S, Slungaard A, Betts B
Transpl Infect Dis
. 2021 Mar;
23(4):e13610.
PMID: 33783930
In the United States, toxoplasmosis following allogeneic hematopoietic stem transplant (allo-HCT) is very rare with a rate only between 0.5% and 2%. The reported rates of hemophagocytic lymphohistiocytosis (HLH) following...
7.
Jurdi N, Rogosheske J, DeFor T, Bejanyan N, Arora M, Bachanova V, et al.
Transplant Cell Ther
. 2020 Oct;
27(1):84.e1-84.e5.
PMID: 33053448
The high incidence of human herpesvirus-6 (HHV-6) reactivation, potentially interfering with engraftment after umbilical cord blood (UCB) hematopoietic cell transplantation (HCT), remains a major challenge. To potentially address this problem,...
8.
Dimaggio E, Zhou J, Caddell R, Tombleson R, Perkins J, Anasetti C, et al.
Leuk Lymphoma
. 2020 Mar;
61(7):1678-1687.
PMID: 32133897
Optimal conditioning chemotherapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains uncertain. Myeloablative regimens such as fludarabine/busulfan are favored over reduced-intensity fludarabine/melphalan (Flu/Mel); however, it is...
9.
Khimani F, McDonald G, Shulman H, Betts B, Locke F, Fernandez H, et al.
Bone Marrow Transplant
. 2018 Jun;
54(1):85-89.
PMID: 29895929
Sirolimus-based graft vs. host disease (GVHD) prophylaxis is associated with higher incidence of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after allogeneic hematopoietic cell transplantation (HCT). However, whether the clinical manifestations and...
10.
Perez L, Fernandez H, Horna P, Riches M, Locke F, Field T, et al.
Bone Marrow Transplant
. 2018 Apr;
53(11):1434-1444.
PMID: 29670210
Glucocorticoids for primary therapy of acute GVHD have limited responses. A phase I/II trial tested 4 weeks of deacetylase inhibitor panobinostat started within 48 h of glucocorticoids (1 mg/kg/day prednisone...